ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Aug 15
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedAug 15, 2025
DataAggregated Company Financials
Companies552
- 7D4.6%
- 3M12.2%
- 1Y-6.5%
- YTD5.1%
Over the last 7 days, the Biotech industry has risen 4.6%, driven by gains in Gilead Sciences and AbbVie of 7.9% and 2.9%, respectively. During this same period, the Summit Therapeutics underperformed, falling 5.8%. However, the industry is down 6.5% over the past year. Looking forward, earnings are forecast to grow by 25% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 15 Aug 2025 | US$1.1t | US$163.7b | -US$18,854,545,748.51 | 15.4x | -56.4x | 6.5x |
| Sun, 13 Jul 2025 | US$973.9b | US$155.8b | -US$23,414,756,764.18 | 18.1x | -41.6x | 6.3x |
| Tue, 10 Jun 2025 | US$952.0b | US$155.9b | -US$23,940,289,678.74 | 17x | -39.8x | 6.1x |
| Thu, 08 May 2025 | US$890.3b | US$155.1b | -US$25,574,283,733.68 | 18.6x | -34.8x | 5.7x |
| Sat, 05 Apr 2025 | US$774.2b | US$118.6b | -US$37,107,737,767.73 | 20.1x | -20.9x | 6.5x |
| Mon, 03 Mar 2025 | US$850.8b | US$118.9b | -US$37,265,127,499.97 | 17x | -22.8x | 7.2x |
| Wed, 29 Jan 2025 | US$991.6b | US$149.5b | -US$26,314,079,099.96 | 17.5x | -37.7x | 6.6x |
| Fri, 27 Dec 2024 | US$990.4b | US$149.9b | -US$26,370,197,964.77 | 16.1x | -37.6x | 6.6x |
| Sun, 24 Nov 2024 | US$1.0t | US$150.0b | -US$26,558,578,256.44 | 16.6x | -38.3x | 6.8x |
| Tue, 22 Oct 2024 | US$908.0b | US$113.1b | -US$36,019,658,167.43 | 21.3x | -25.2x | 8x |
| Thu, 19 Sep 2024 | US$925.6b | US$113.2b | -US$35,972,157,840.12 | 22.6x | -25.7x | 8.2x |
| Sat, 17 Aug 2024 | US$882.4b | US$113.2b | -US$35,765,976,434.68 | 22.3x | -24.7x | 7.8x |
| Mon, 15 Jul 2024 | US$1.2t | US$164.5b | -US$28,105,214,748.90 | 29.4x | -42.5x | 7.3x |
| Wed, 12 Jun 2024 | US$1.2t | US$164.5b | -US$26,795,949,828.09 | 28.2x | -43.3x | 7.1x |
| Fri, 10 May 2024 | US$1.1t | US$164.8b | -US$26,733,495,747.45 | 23.2x | -41.9x | 6.8x |
| Sun, 07 Apr 2024 | US$1.1t | US$164.4b | -US$23,431,530,428.03 | 21.3x | -48.2x | 6.9x |
| Tue, 05 Mar 2024 | US$1.2t | US$167.9b | -US$21,298,840,556.03 | 15.9x | -56x | 7.1x |
| Thu, 01 Feb 2024 | US$1.4t | US$204.7b | -US$22,672,999,235.00 | 17.8x | -63.6x | 7x |
| Sat, 30 Dec 2023 | US$1.4t | US$204.9b | -US$22,199,644,413.00 | 19.8x | -62.9x | 6.8x |
| Mon, 27 Nov 2023 | US$1.2t | US$204.8b | -US$22,013,452,568.00 | 18.6x | -55.7x | 6x |
| Wed, 25 Oct 2023 | US$1.2t | US$207.5b | -US$13,040,888,319.00 | 16.2x | -93x | 5.8x |
| Fri, 22 Sep 2023 | US$1.3t | US$207.5b | -US$12,875,537,971.00 | 17.1x | -98.4x | 6.1x |
| Sun, 20 Aug 2023 | US$1.3t | US$207.6b | -US$12,372,676,716.00 | 17.6x | -102.2x | 6.1x |
| Tue, 18 Jul 2023 | US$1.1t | US$186.7b | -US$15,958,556,257.00 | 12.9x | -71.1x | 6.1x |
| Thu, 15 Jun 2023 | US$1.2t | US$186.1b | -US$15,929,018,280.00 | 11.7x | -72.3x | 6.2x |
| Sat, 13 May 2023 | US$1.2t | US$191.7b | -US$12,347,110,804.00 | 13.8x | -93.5x | 6x |
| Mon, 10 Apr 2023 | US$1.2t | US$198.3b | -US$3,291,225,770.00 | 14x | -353.5x | 5.9x |
| Wed, 08 Mar 2023 | US$1.1t | US$198.7b | -US$5,119,400,088.00 | 15.9x | -221.2x | 5.7x |
| Fri, 03 Feb 2023 | US$1.2t | US$203.9b | US$1.8b | 14.9x | 642.4x | 5.7x |
| Sun, 01 Jan 2023 | US$1.1t | US$203.5b | US$1.7b | 14.3x | 663.5x | 5.6x |
| Tue, 29 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.7x | 841.8x | 5.5x |
| Thu, 27 Oct 2022 | US$1.1t | US$206.5b | US$6.4b | 14.1x | 171.7x | 5.3x |
| Sat, 24 Sep 2022 | US$1.0t | US$206.0b | US$5.6b | 13.9x | 182.3x | 4.9x |
| Mon, 22 Aug 2022 | US$1.1t | US$206.4b | US$7.3b | 16x | 147.7x | 5.2x |
Price to Earnings Ratio
147.7x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 7.4% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.65% | |
| Healthcare | 4.18% | |
| Biotech | 4.56% | |
| Biotech | 4.56% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$119.02 | 7.9% +US$10.8b | 60.1% | PE23.4x | |
| ABBV AbbVie | US$204.68 | 2.9% +US$10.3b | 5.8% | PE97.1x | |
| INSM Insmed | US$127.75 | 16.9% +US$3.9b | 72.3% | PS67.8x | |
| VRTX Vertex Pharmaceuticals | US$390.30 | 3.9% +US$3.8b | -17.3% | PE27.5x | |
| AMGN Amgen | US$290.29 | 2.0% +US$3.0b | -10.8% | PE23.6x |
